My Question to the Board is: At what point are we currently´?

Generex website:

Generex & Epivax have identified SARS-COV-2 amino acid
peptides for epitope evaluation
2. Synthesize 2019-nCoV epitope peptides for screening (standard
peptide chemistry – 11 - 15 amino acids)
3. Screen common HLA-DR alleles in vitro vs SARS-COV-2
sequences
4. Test chemical linkers with for best fit for Ii-Key (LRMK) hybrid
vaccine – optimize for immunogenicity
5. Select Ii-Key Hybrid/2019-nCoV peptides for vaccine evaluation
6. Collect blood samples & isolate PBMCs from 2019-nCoV
infected & recovered individuals
7. Test Ii-Key/ SARS-COV-2 hybrid peptide vaccines vs. PBMcs
8. Conduct Elispot analysis to test for IFN-γ expression indicating
CD-4 T-cell activation
9. Select active Ii-Key/ SARS-COV-2 hybrid peptide vaccines for
human clinical testing
10. Conduct Clinical Trial with Lead Ii-Key/SARS-COV-2 Peptides
• Evaluate safety & immunogenicity (DTH Assay)
11. Select peptides for Multi-valent Ii-Key/ SARS-COV-2 Peptide
Vaccine
12. Commercial Manufacturing & Distribution in 5 to 9 months